We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    ORA-D-015
Previous Study | Return to List | Next Study

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03467932
Recruitment Status : Completed
First Posted : March 16, 2018
Last Update Posted : April 3, 2020
Information provided by (Responsible Party):
Oramed, Ltd.

Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the ClinicalTrials.gov Results Quality Control (QC) review process. Results information is submitted to ClinicalTrials.gov by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on ClinicalTrials.gov (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status : Completed
Actual Primary Completion Date : October 21, 2019
Actual Study Completion Date : February 18, 2020
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 September 19, 2021
(Canceled on September 21, 2021)
October 14, 2021
November 12, 2021 Submission with QC Comments
2 December 7, 2021
January 4, 2022 Submission with QC Comments
3 January 31, 2022
February 23, 2022 Submission with QC Comments
4 June 3, 2022
June 29, 2022 Submission with QC Comments
5 September 11, 2022